Loading...
•
Jun 30, 2021
Eton Q2 2021 Earnings Report
Reported increased adoption of ALKINDI SPRINKLE and acquired rights to ZENEO Hydrocortisone autoinjector.
Key Takeaways
Eton Pharmaceuticals reported revenue of $3.1 million for the second quarter of 2021, which included $2.5 million of licensing revenue. The company also reported a net loss of $2.0 million, with an EPS of ($0.08).
Received FDA-approval for Rezipres® during the second quarter.
Expanded pediatric endocrinology portfolio with the acquisition of U.S. and Canadian rights to the ZENEO® Hydrocortisone autoinjector.
ALKINDI SPRINKLE sales force prioritized in-person meetings due to fewer COVID-19 restrictions.
More than 90% of patients on ALKINDI SPRINKLE treatment are being reimbursed.
Eton
Eton
Eton Revenue by Segment
Revenue by Segment
Licensing Revenue
CapyFin.com